Literature DB >> 24315440

Correction of a genetic disease in mouse via use of CRISPR-Cas9.

Yuxuan Wu1, Dan Liang, Yinghua Wang, Meizhu Bai, Wei Tang, Shiming Bao, Zhiqiang Yan, Dangsheng Li, Jinsong Li.   

Abstract

The CRISPR-Cas9 system has been employed to generate mutant alleles in a range of different organisms. However, so far there have not been reports of use of this system for efficient correction of a genetic disease. Here we show that mice with a dominant mutation in Crygc gene that causes cataracts could be rescued by coinjection into zygotes of Cas9 mRNA and a single-guide RNA (sgRNA) targeting the mutant allele. Correction occurred via homology-directed repair (HDR) based on an exogenously supplied oligonucleotide or the endogenous WT allele, with only rare evidence of off-target modifications. The resulting mice were fertile and able to transmit the corrected allele to their progeny. Thus, our study provides proof of principle for use of the CRISPR-Cas9 system to correct genetic disease.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24315440     DOI: 10.1016/j.stem.2013.10.016

Source DB:  PubMed          Journal:  Cell Stem Cell        ISSN: 1875-9777            Impact factor:   24.633


  229 in total

1.  Target specificity of the CRISPR-Cas9 system.

Authors:  Xuebing Wu; Andrea J Kriz; Phillip A Sharp
Journal:  Quant Biol       Date:  2014-06

2.  Genetic therapies: Correcting genetic defects with CRISPR-Cas9.

Authors:  Isabel Lokody
Journal:  Nat Rev Genet       Date:  2013-12-17       Impact factor: 53.242

Review 3.  Non-viral delivery systems for CRISPR/Cas9-based genome editing: Challenges and opportunities.

Authors:  Ling Li; Shuo Hu; Xiaoyuan Chen
Journal:  Biomaterials       Date:  2018-04-18       Impact factor: 12.479

4.  Introducing precise genetic modifications into human 3PN embryos by CRISPR/Cas-mediated genome editing.

Authors:  Xiangjin Kang; Wenyin He; Yuling Huang; Qian Yu; Yaoyong Chen; Xingcheng Gao; Xiaofang Sun; Yong Fan
Journal:  J Assist Reprod Genet       Date:  2016-04-06       Impact factor: 3.412

Review 5.  CRISPR-based technologies: prokaryotic defense weapons repurposed.

Authors:  Rebecca M Terns; Michael P Terns
Journal:  Trends Genet       Date:  2014-02-18       Impact factor: 11.639

6.  Genome editing with CRISPR/Cas9 in postnatal mice corrects PRKAG2 cardiac syndrome.

Authors:  Chang Xie; Ya-Ping Zhang; Lu Song; Jie Luo; Wei Qi; Jialu Hu; Danbo Lu; Zhen Yang; Jian Zhang; Jian Xiao; Bin Zhou; Jiu-Lin Du; Naihe Jing; Yong Liu; Yan Wang; Bo-Liang Li; Bao-Liang Song; Yan Yan
Journal:  Cell Res       Date:  2016-08-30       Impact factor: 25.617

7.  Optimizing CRISPR/Cas9 technology for precise correction of the Fgfr3-G374R mutation in achondroplasia in mice.

Authors:  Kai Miao; Xin Zhang; Sek Man Su; Jianming Zeng; Zebin Huang; Un In Chan; Xiaoling Xu; Chu-Xia Deng
Journal:  J Biol Chem       Date:  2018-11-28       Impact factor: 5.157

8.  Regulation of IL12B Expression in Human Macrophages by TALEN-mediated Epigenome Editing.

Authors:  Meng Chen; Hua Zhu; Yu-Juan Mao; Nan Cao; Ya-Li Yu; Lian-Yun Li; Qiu Zhao; Min Wu; Mei Ye
Journal:  Curr Med Sci       Date:  2020-10-29

Review 9.  CRISPR/Cas9: molecular tool for gene therapy to target genome and epigenome in the treatment of lung cancer.

Authors:  M Sachdeva; N Sachdeva; M Pal; N Gupta; I A Khan; M Majumdar; A Tiwari
Journal:  Cancer Gene Ther       Date:  2015-10-23       Impact factor: 5.987

Review 10.  The new CRISPR-Cas system: RNA-guided genome engineering to efficiently produce any desired genetic alteration in animals.

Authors:  Davide Seruggia; Lluis Montoliu
Journal:  Transgenic Res       Date:  2014-08-06       Impact factor: 2.788

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.